XML 63 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments and Fair Value Measurements (Tables)
 3 Months Ended
Mar. 27, 2020
Fair Value Disclosures [Abstract]  
Schedule of Share-based Payment Awared, Warrants, Valuation Assumptions [Table Text Block] [Table Text Block]
The key assumptions used to estimate the fair value of the Settlement Warrants were as follows:
 
March 27, 2020
 
December 27, 2019
Expected share price volatility
64.1
%
 
54.4
%
Weighted-average risk-free rate
0.6
%
 
1.8
%
Expected annual dividend per share
—
%
 
—
%
Weighted-average expected term (in years)
7.6

 
7.6

Share price
$
2.23

 
$
3.45
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

March 27,
2020

Quoted Prices in Active Markets for Identical Assets
(Level 1)

Significant Other Observable Inputs
(Level 2)

Significant Unobservable Inputs
(Level 3)
Assets:








Debt and equity securities held in rabbi trusts
$
28.6

 
$
19.3

 
$
9.3

 
$
—

Equity securities
29.2

 
29.2

 
—

 
—

 
$
57.8

 
$
48.5

 
$
9.3

 
$
—


 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Deferred compensation liabilities
$
27.5

 
$
—

 
$
27.5

 
$
—

Contingent consideration and acquired contingent liabilities
68.8

 
—

 
—

 
68.8

Settlement Warrants
26.6

 
—

 
—

 
26.6


$
122.9

 
$
—

 
$
27.5

 
$
95.4

 
December 27,
2019
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Debt and equity securities held in rabbi trusts
$
30.6

 
$
21.0

 
$
9.6

 
$
—

Equity securities
26.2

 
26.2

 
—

 
—

 
$
56.8

 
$
47.2

 
$
9.6

 
$
—

 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
Deferred compensation liabilities
$
39.2

 
$
—

 
$
39.2

 
$
—

Contingent consideration and acquired contingent liabilities
69.3

 
—

 
—

 
69.3

Settlement Warrants
43.4

 
—

 
—

 
43.4

 
$
151.9

 
$
—

 
$
39.2

 
$
112.7
Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities The following table summarizes the activity for contingent consideration:
Balance as of December 27, 2019
$
69.3

Accretion expense
0.3

Fair value adjustments
(0.8
)
Balance as of March 27, 2020
$
68.8
Schedule of Carrying Amount and Fair Value of Long-term Debt The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period:

March 27, 2020

December 27, 2019

Carrying
Value

Fair
Value

Carrying
Value

Fair
Value
Level 1:
 
 
 
 
 
 
 
4.875% senior notes due April 2020
$
614.8

 
$
408.9

 
$
614.8

 
$
480.0

5.75% senior notes due August 2022
610.3

 
283.3

 
610.3

 
251.0

4.75% senior notes due April 2023
133.7

 
28.8

 
133.7

 
53.7

5.625% senior notes due October 2023
514.7

 
131.2

 
514.7

 
193.2

5.50% senior notes due April 2025
387.2

 
76.1

 
387.2

 
135.5

10.00% second lien senior notes due April 2025
322.9

 
221.9

 
322.9

 
253.8

Revolving credit facility
900.0

 
900.0

 
900.0

 
900.0

Level 2:
 
 
 
 
 
 
 
9.50% debentures due May 2022
10.4

 
5.2

 
10.4

 
5.4

8.00% debentures due March 2023
4.4

 
1.6

 
4.4

 
2.0

Term loan due September 2024
1,516.9

 
1,026.3

 
1,520.8

 
1,240.0

Term loan due February 2025
402.6

 
270.2

 
403.6

 
326.2

Total Debt
$
5,417.9

 
$
3,353.5

 
$
5,422.8

 
$
3,840.8
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales:
 
Three Months Ended
 
March 27,
2020
 
March 29,
2019
CuraScript, Inc.
24.6
%
 
27.5
%

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
 
March 27,
2020
 
December 27,
2019
AmerisourceBergen Corporation
31.1
%
 
31.3
%
McKesson Corporation
18.5

 
15.3

CuraScript, Inc.
*

 
12.1

*Accounts receivable attributable to this distributor were less than 10.0% of total gross accounts receivable during the respective period presented above.
The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales:

Three Months Ended

March 27,
2020
 
March 29,
2019
Acthar Gel
25.2
%
 
28.3
%
INOmax
21.3

 
19.1

Ofirmev
11.3

 
12.1